Posted by Michael Wonder on 18 Oct 2021
EMA grants PRIME designation for JR-141 for the treatment of mucopolysaccharidosis type II (Hunter syndrome)
18 October 2021 - JCR Pharmaceuticals announced today that the EMA has granted PRIME designation for the investigational drug JR-141 (pabinafusp alfa) for the treatment of mucopolysaccharidosis II (Hunter syndrome).
JR-141 is a recombinant fusion protein of antibody against the human transferrin receptor and idursulfase, the enzyme missing or malfunctioning in subjects with mucopolysaccharidosis II.
